Atria Investments Inc Buys 3,941 Shares of Zoetis Inc. (NYSE:ZTS)

Atria Investments Inc boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 95,809 shares of the company’s stock after acquiring an additional 3,941 shares during the period. Atria Investments Inc’s holdings in Zoetis were worth $15,610,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Darwin Wealth Management LLC bought a new position in Zoetis in the 3rd quarter worth $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the third quarter worth about $33,000. Dunhill Financial LLC raised its stake in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.4 %

ZTS stock opened at $169.79 on Wednesday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The stock has a market capitalization of $76.03 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm’s fifty day simple moving average is $166.53 and its two-hundred day simple moving average is $177.06.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.18%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

Several research firms have recently issued reports on ZTS. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Leerink Partners started coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, StockNews.com cut Zoetis from a “buy” rating to a “hold” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $215.90.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.